For some time we’ve been pointing out the massive pile of evidence that THC and other cannabinoids have potential as anticancer drugs. A new study out of Thailand demonstrates that THC can fight cholangiocarcinoma – cancer of the bile duct. This is a rare but deadly form of cancer, with only 30 percent of patients still alive after five years, according to the  Cholangiocarcinoma Foundation. Based on these new lab results, the Thai researchers conclude, “THC is potentially used to retard cholangiocarcinoma cell growth and metastasis.”

The battle in L.A. is not over yet, but two City Council committees have rejected draconian and bad advice from City Attorney Carmen Trutanich, the Los Angeles Times reports.

In case anyone needs proof of the mass media’s tendency to repeat government pronouncements without bothering to check their accuracy, here’s a small but telling example:

Inexplicably, when the U.S. Department of Justice issued a memo last month explaining that it would generally refrain from prosecuting medical marijuana activities that are clearly legal under state law, it mistakenly indicated that there are 14 medical marijuana states. DOJ’s goof was to include Maryland, where medical marijuana is not actually legal, but where state law provides for reduced penalties to patients who successfully present a medical-necessity defense.

DOJ’s goof has now traveled though most of the known universe, repeated by credulous news media. The Associated Press, after talking to MPP, at least included an explanatory note about the discrepancy, but others just repeated the mistake with no explanation, including Katie Couric of CBS, the  Washington Post, Voice of America, the Guardian of London, and even the editorial page of the New York Times.

C’mon, guys, tell me that fact-checking isn’t entirely dead. Kudos to those media outlets that got it right, including CNN.

In its official response to the AMA’s recent call for a review of marijuana’s status as a Schedule I drug (barring any medical use) under federal law, the White House Office of National Drug Control Policy stated that it would defer to “the FDA’s judgment that the raw marijuana plant cannot meet the standards for identity, strength, quality, purity, packaging and labeling required of medicine.”

While we’re not used to factual accuracy from ONDCP, in this case they’re wrong not once, but twice.

First, there is absolutely no reason that plant medicines can’t be standardized and controlled for purity and potency. Indeed, the Netherlands has been doing just that for years, with medical marijuana distributed in Dutch pharmacies that is “of pharmaceutical quality and complies with the strictest requirements,” according to the Dutch government.

Second, the FDA has never said that a natural plant product can’t be a medicine. Indeed the agency has a lengthy “Guidance for Industry: Botanical Drug Products,” specifically designed to aid developers of plant medicines. The document not only doesn’t rule out plants as medicines, it even states, “In the initial stage of clinical studies of a botanical drug, it is generally not necessary to identify the active constituents or other biological markers or to have a chemical identification and assay for a particular constituent or marker.” Given that the active components of marijuana are already well-known and extensively researched, marijuana is well ahead of where the FDA says plant products need to be to start the process of seeking FDA licensing.

Yes, the FDA did put out a press release in 2006 saying that “smoked marijuana” had not been shown to be a safe and effective medicine. That statement was utterly unscientific, as we pointed out at the time, but it was absolutely not a declaration that the plant could never be a medicine.

There has long been reason to think that marijuana may be helpful to some patients with bipolar disorder, as certain cannabinoids have been shown in lab and animal studies to have effects that ought to be beneficial. Now, a new study from the University of Oslo finds that marijuana use is associated with better neurocognitive functioning in bipolar patients. In various tests of memory, learning, etc., bipolar patients who used marijuana did better than those who didn’t use it – the exact opposite of what the researchers found in patients with schizophrenia, a condition marijuana can sometimes worsen. “The findings,” the scientists write, “suggest that cannabis use may be related to improved neurocognition in bipolar disorder.”